New Developments in the Diagnosis
and Treatment of Psoriatic Arthritis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie and Lilly USA LLC

Description:
Psoriatic arthritis is a debilitating, progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations that affect men and women equally. Patients often experience extreme pain and joint damage which affect their quality of life, physical function, and ability to work. Approximately 30% to 40% of people with psoriasis will also develop psoriatic arthritis, a painful and potentially disfiguring condition that remains underdiagnosed. Symptoms include fatigue, joint inflammation, and potentially progressive joint damage. Diagnosis may be easier to confirm if psoriasis coexists with symptoms of arthritis. However, in as many as 15% of cases, symptoms of psoriatic arthritis appear before symptoms of psoriasis. A careful medical history, physical examination, blood tests, magnetic resonance imaging (MRI), and x-rays of the involved joints along with a dermatologic evaluation may be used to diagnose psoriatic arthritis. In addition to early diagnosis, the goal of treatment for psoriatic arthritis is to properly manage the disease by obtaining remission; which includes prompt, aggressive treatment aimed at limiting joint damage and clearing skin psoriasis. Nonsteroidal anti-inflammatory drugs (NSAIDs) and traditional disease-modifying antirheumatic drugs (DMARDs) are used to reduce inflammation caused by arthritis with the intent of reducing pain, swelling and stiffness. However, many of these medications suppress the immune system and lead to a potential increase risk of infections. Thankfully novel biologic treatments have been developed and have been proven to stop joint damage as well as pain and swelling in moderate to severe psoriatic arthritis.

Upon Completion of this activity, participants will be able to:

  • Explore the safety and efficacy of current and emerging treatments, including the mechanism of action of newer biologics

  • Assess the latest developments in screening tools that identify patients at risk for psoriatic arthritis

  • Identify the common comorbidities in patients with psoriatic arthritis

  • Analyze strategies on how effective systematic therapies might be used in clinical practice

  • Discuss the latest research developments and guidelines in the management of psoriatic arthritis
     

Faculty: Atul Deodhar, MD, MRCP
Professor of Medicine
Medical Director
Rheumatology Clinics
Oregon Health & Science University
OHSU Division of Arthritis & Rheumatic Diseases

Disclosure:

Dr. Deodhar serves as an advisor or consultant for Eli Lilly, Janssen, Novartis, Pfizer and UCB. He receives grants for clinical research from Amgen, AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB.  His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie and Lilly USA LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue